Ian Eliason Email & Phone Number

Seattle, Washington, Us

Zoic is an IP centric life sciences venture fund. We are actively seeking to invest in early stage companies that:1. Have technology with a primary medical application; any technology except for those considered a pharmaceutical by the FDA.2. The technology represents 10x magnitudes of improvement over current standard of care, or has no equivalent.3. We prefer unique hardware and IP coupled with unique software.4. Technology has the potential to be used as a platform for multiple medical, and possibly non-medical, applications.5. Currently raising in the seed round, or before any regulatory approval with some feasibility work done.Specific examples including: molecular diagnostics, particularly for direct to consumer use, noninvasive imaging, noninvasive diagnostics and therapies for mental health, surgical tools, synthetic cardiovascular components.

Seattle, Washington, Us

Investor in HDT Bio. A biopharmaceutical company addressing the urgent need for cost-effective vaccines to prevent infectious diseases across the globe.HDT Bio, was formed by a group of experienced entrepreneurs with decades of success in biopharmaceutical research and vaccine development around the world.

Morrisville, North Carolina, Us

Investor in Trio Labs. Trio Labs' mission is to improve lives by enabling the next generation of medical devices. Trio fabricates precision metal parts with unmatched fine resolution that scale seamlessly from prototyping though high volume manufacturing. The Resin Infused Powder Lithography (RIPL) process reduces costs and manufacturing times for existing products, and enables wholly new solutions in a wide range of medical device markets such as high precision surgical tools, interventional devices, miniaturized infusion pumps, microneedle arrays, drug delivery devices, and more.

Ambler, Pa, Us

Investor in Chromatan. The future of single-use, column-free purification.Purification of proteins and vaccines is vital to biotechnology. Innovation in this industry has lagged, leading to manufacturing bottlenecks, especially in antibody production. ChromaTan has developed Continuous Countercurrent Tangential Chromatography (CCTC) - a new column-free and single-use process that provides a cost saving alternative to column chromatography.ChromaTan's proprietary Countercurrent Tangential Chromatography technology uses an innovative membrane solution to provide the same high level of purification afforded by conventional column designs, with continous output and up to 80% less resin consumption.

Fremont, California, Us

Investor in Probius. Bridging biology and AI, to improve human health. Empowering the future of life science research.

Montreal, Ca

Montreal, Ca

Investor in Reveal Surgical/ODS Medical.

Montreal, Ca

ODS Medical Inc. is a medical device company that seeks to commercialize our exclusive Raman spectroscopy system for real-time detection of tissue abnormalities through the development, manufacture and sales of products for a range of clinical settings.

Montréal, Qc, Ca

Investor in Optina Diagnostics. Optina aims to transform memory loss detection and understanding through a simple eye exam offered in near-patient clinicsOptina at the forefront of innovation To deliver new insights on the most complex and least understood organ, the brain.Alzheimer’s disease is a leading cause of disability and dependency in later life. This condition remains complex and difficult to assess, even by experts.

Boston, Ma, Us

Investor in BioRosa. The Future of Autism Spectrum Disorder DetectionBioROSA’s Test Provides a New Way to Detect ASDBioROSA is developing a highly accurate blood test that will detect ASD in children as young as 18 months.Early Intervention FollowsA positive BioROSA test can allow for early intervention services to begin. Early intervention has been shown to improve language, social skills, and IQ for many children with ASD2.The BioROSA test uses a small amount of blood taken from a standard blood draw. They measure a set of blood biomarkers that are predictors of ASD. Computer algorithms are applied to analyze data and provide a risk score for ASD.

San Carlos, California, Us

Investor in InnoVein. InnoVein, a Y Combinator and venture backed medical device company, is developing a first-of-its-kind valve replacement to offer patients their first definitive cure. Its novel award-winning technology is predicated on decades of cardiac and arterial approaches.In aggregate, the InnoVein founding team has invented and brought over 15 medical technologies to market, with leading products selling over $3B.

San Diego, Ca, Us

Investor in Juno Diagnostics. Juno Diagnostics has developed the next generation of non-invasive prenatal tests so that all women can access a higher standard of care.The company founders worked together to pioneer the development and commercialization of the first cell-free DNA-based non-invasive prenatal screen (NIPS) in the United States, trusted by doctors for millions of pregnancies each year.